Cargando…
A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population
BACKGROUND: Population-based studies on COVID-19 have important implications for modeling the pandemic and determining vaccination policies. Limited data are available from such surveys in Egypt. METHODS: This cross-sectional was conducted throughout the period between January and June 2021, which c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364299/ https://www.ncbi.nlm.nih.gov/pubmed/35948951 http://dx.doi.org/10.1186/s41182-022-00448-x |
_version_ | 1784765120697597952 |
---|---|
author | El-Ghitany, Engy Mohamed Farag, Shehata Farghaly, Azza Galal Hashish, Mona H. Hassaan, Mahmoud A. Omran, Eman A. |
author_facet | El-Ghitany, Engy Mohamed Farag, Shehata Farghaly, Azza Galal Hashish, Mona H. Hassaan, Mahmoud A. Omran, Eman A. |
author_sort | El-Ghitany, Engy Mohamed |
collection | PubMed |
description | BACKGROUND: Population-based studies on COVID-19 have important implications for modeling the pandemic and determining vaccination policies. Limited data are available from such surveys in Egypt. METHODS: This cross-sectional was conducted throughout the period between January and June 2021, which coincided with the second and third waves of the COVID-19 pandemic in Egypt. At that time, vaccines against COVID-19 were not available to the general population. The study was carried out in eight Egyptian governorates and included 2360 participants, who were recruited through a multistage stratified cluster sample technique, based on gender, age, and district followed by a random sample within each district. Socio-demographic data were recorded and serum samples were collected and tested for SARS-Co-V2 spike (S) antibodies. RESULTS: The overall adjusted prevalence of anti-S was 46.3% (95% CI 44.2–48.3%), with significant differences between governorates. Factors associated with anti-S seropositivity were: being female (p = 0.001), living in a rural area (p = 0.008), and reporting a history of COVID-19 infection (p = 0.001). Higher medians of anti-S titers were significantly associated with: extremes of age (p < 0.001), living in urban areas, having primary education (p = 0.009), and reporting a history of COVID-19 infection, especially if based on chest CT or PCR (p < 0.001). CONCLUSIONS: High seroprevalence rates indicate increased COVID-19 infection and immune response among a considerable percentage of the community. Age, gender, residence, educational level, and previous PCR-confirmed COVID-19 infections were all determinants of the immune response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41182-022-00448-x. |
format | Online Article Text |
id | pubmed-9364299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93642992022-08-10 A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population El-Ghitany, Engy Mohamed Farag, Shehata Farghaly, Azza Galal Hashish, Mona H. Hassaan, Mahmoud A. Omran, Eman A. Trop Med Health Research BACKGROUND: Population-based studies on COVID-19 have important implications for modeling the pandemic and determining vaccination policies. Limited data are available from such surveys in Egypt. METHODS: This cross-sectional was conducted throughout the period between January and June 2021, which coincided with the second and third waves of the COVID-19 pandemic in Egypt. At that time, vaccines against COVID-19 were not available to the general population. The study was carried out in eight Egyptian governorates and included 2360 participants, who were recruited through a multistage stratified cluster sample technique, based on gender, age, and district followed by a random sample within each district. Socio-demographic data were recorded and serum samples were collected and tested for SARS-Co-V2 spike (S) antibodies. RESULTS: The overall adjusted prevalence of anti-S was 46.3% (95% CI 44.2–48.3%), with significant differences between governorates. Factors associated with anti-S seropositivity were: being female (p = 0.001), living in a rural area (p = 0.008), and reporting a history of COVID-19 infection (p = 0.001). Higher medians of anti-S titers were significantly associated with: extremes of age (p < 0.001), living in urban areas, having primary education (p = 0.009), and reporting a history of COVID-19 infection, especially if based on chest CT or PCR (p < 0.001). CONCLUSIONS: High seroprevalence rates indicate increased COVID-19 infection and immune response among a considerable percentage of the community. Age, gender, residence, educational level, and previous PCR-confirmed COVID-19 infections were all determinants of the immune response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41182-022-00448-x. BioMed Central 2022-08-10 /pmc/articles/PMC9364299/ /pubmed/35948951 http://dx.doi.org/10.1186/s41182-022-00448-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research El-Ghitany, Engy Mohamed Farag, Shehata Farghaly, Azza Galal Hashish, Mona H. Hassaan, Mahmoud A. Omran, Eman A. A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title | A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title_full | A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title_fullStr | A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title_full_unstemmed | A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title_short | A pre-vaccine exploratory survey of SARS-CoV-2 humoral immunity among Egyptian general population |
title_sort | pre-vaccine exploratory survey of sars-cov-2 humoral immunity among egyptian general population |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364299/ https://www.ncbi.nlm.nih.gov/pubmed/35948951 http://dx.doi.org/10.1186/s41182-022-00448-x |
work_keys_str_mv | AT elghitanyengymohamed aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT faragshehata aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT farghalyazzagalal aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT hashishmonah aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT hassaanmahmouda aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT omranemana aprevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT elghitanyengymohamed prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT faragshehata prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT farghalyazzagalal prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT hashishmonah prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT hassaanmahmouda prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation AT omranemana prevaccineexploratorysurveyofsarscov2humoralimmunityamongegyptiangeneralpopulation |